This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)(Learn how and when to remove this template message)
|Traded as||SSE: 603259|
|Industry||Contract Research Organizations|
Number of locations
|18, including in China and USA|
|Dr. Ge Li|
Number of employees
|Subsidiaries||Genuity Science (2015- )|
The company covers the development cycle through five core operations, including small molecule R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics.
WuXi's founder is Dr. Ge Li, an organic chemist, who founded WuXi PharmaTech in Shanghai in December 2000.
WuXi established services in synthetic chemistry in 2001, manufacturing process development in 2003, research manufacturing in 2004, bioanalytical services in 2005, service biology in 2006, and toxicology and formulation in 2007. On December 14, 2006, WuXi PharmaTech announced that it was ranked 173rd on the Deloitte Technology Fast 500 Asia Pacific 2006. The company opened chemistry facilities in Tianjin in 2007. In 2008, WuXi PharmaTech acquired AppTec Laboratory Services Inc., a US-based company founded in 2001 with expertise in medical-device and biologics testing and with facilities in St. Paul, MN; Philadelphia, PA; and Atlanta, GA. WuXi opened a toxicology facility in Suzhou in 2009.
WuXi opened a large-scale manufacturing facility in Jinshan in 2010. The company began a biologics discovery, development, and manufacturing operation in Shanghai and Wuxi City in 2011. At the same year, WuXi acquired MedKey, a China-based clinical research company, and Abgent, a San Diego company and one of the world's largest manufacturers of antibodies for biological research and drug discovery. In 2012, WuXi opened a chemistry facility in Wuhan and a GMP biologics drug-substance facility in Wuxi City. That year WuXi also entered into a joint venture with MedImmune and Kevin Tucker, the biologics arm of AstraZeneca, to co-develop MEDI5117, an anti-IL6 antibody for rheumatoid arthritis for the Chinese market. In 2013, WuXi formed a joint venture with the global clinical contract research organization PRA International (now called PRA Health Sciences) to build a clinical research business in China.
In 2014, WuXi opened a new biologics biosafety testing facility in Suzhou. In the same year, WuXi acquired XenoBiotic Laboratories, Inc. (XBL), a contract research organization with 27 years of operation that provides bioanalytical, drug metabolism, and pharmacokinetic services to the pharmaceutical, animal health, and agrochemical industries.
In 2015, WuXi completed its merger with WuXi Merger Limited, a wholly owned subsidiary of New WuXi Life Science Limited. As a result of the merger, New WuXi Life Science Limited acquired the Company in a cash transaction valued at approximately US$3.3 billion. In 2016, WuXi’s STA subsidiary opened a new campus in Changzhou and operations in San Diego. In the same year, WuXi acquired Crelux GmbH, a structure-based drug discovery provider based in Munich, Germany. In 2017, WuXi acquired HD Biosciences (HDB), a biology focused preclinical drug discovery contract research organization (CRO).
Company segments and subsidiaries
WuXi AppTec provides services to its customers primarily in the pharmaceutical, biotech, and other life science industries, as well as research institutes, disease-focused and non-profit foundations. There are 5 areas of focus for services:
- Small Molecule Therapeutics R&D, Manufacturing and Testing
- Biologicals Therapeutics R&D and Manufacturing
- Gene- and Cell-based Therapies Manufacturing
- Medical Device Testing
- Genomics and Molecular Diagnostics.
In 2015, the company launched the subsidiary WuXi NextCODE following the acquisition of NextCODE Health, a bioinformatics startup company which emerged from the Icelandic firm deCODE genetics in 2013. The subsidiary had offices in Boston and Woburn, Massachusetts (US); Dublin (Ireland), Reykjavik (Iceland) and Shanghai (China). In 2019, the subsidary sought to divest its Chinese operations following changes to the country's Human Genetic Resource Regulation and a standing relationship with Huawei, both of which raised security concerns for the company as a whole. A buyer for the Shanghai facility had not been achieved by mid-2020, at which point the company changed its name to Genuity Science, having completed a round of internal reorganization.
- "Company Profile". WuXi AppTec. Archived from the original on 5 July 2017. Retrieved 12 July 2017.
- "WuXi PharmaTechListed Among Asia's Fastest Growing Companies, Third Year Running" (Press release). WuXi PharmaTech. 14 December 2006. Retrieved 24 June 2020 – via PRNewswire.
- "Our History". WuXi AppTec. 29 March 2019. Retrieved 24 June 2020.
- Fidler, Ben (23 October 2013). "DeCode Spinout, NextCode Health, Launches With $15M From Arch, Polaris". Xconomy. Boston. Retrieved 24 June 2020.
- "WuXi NextCode". Fast Company. 22 April 2020. Retrieved 24 June 2020.
- Staff (23 June 2020). "WuXi NextCode Restructures, Rebrands as Genuity Science". genomeweb. New York City: Crain Communications. Retrieved 24 June 2020.
- WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results
- WuXi PharmaTech Announces First-Quarter 2013